CISPLATIN PLUS VP16 AS SALVAGE TREATMENT FOR ADVANCED BREAST-CARCINOMA RESISTANT OR RECURRENT AFTER 1ST LINE CHEMOTHERAPY FOR METASTATIC DISEASE
- B FERRERO
- V GEBBIA
- G CANNATA
- S GIUFFRE
- R VALENZA
- A TESTA
- M TIRRITO
- N GEBBIA
Affiliations: HOSP VILLA GERANEI,TRAPANI,ITALY. UNIV PALERMO,INST PHARMACOL,SERV CHEMOTHERAPY,I-90134 PALERMO,ITALY. UNIV PALERMO,DEPT ANAT & SURG,I-90134 PALERMO,ITALY.
- Published online on: March 1, 1995 https://doi.org/10.3892/or.2.2.299
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Forty patients with chemotherapy refractory metastatic breast carcinoma were enrolled in a phase II study of cisplatin 80 mg/m2 on day 1 plus VP16 100 mg/m2 on days 1-3 every 28 days. The overall response rate was 32% (95% CL 17-47%), with 2 patients (5%) showing a CR with a mean duration of 11.3 months, and 11 patients (27%) a PR with a mean duration of 7.8+ months. Seven patients (17%) had stable disease, and 20 patients (50%) progressed despite chemotherapy. One complete response and 4 partial responses were obtained in patients previously untreated with antracyclines. The overall survival was 10.2+ months. The mean survival of responding patients (CR+PR) was 15.5+ months, while that of non responders (NC+PD) was 8.6+ months. A total of 188 cycles were administered (4.7 cycles/patient) and the most frequent toxicities were gastrointestinal and hematological side-effects. The most severe toxicities were intense vomiting and anemia. Grade 3 vomiting was seen in 11 patients (27%), and grade 1-2 anemia in 30% of cases. Severe grade 3 leukopenia was seen in only 12% of cases. Mild renal toxicity was recorded only in 2 cases, while alopecia was observed in almost all patients. In conclusion, although CDDP plus VP16 regimen, may be safely given on an outpatient basis, its routine use as salvage treatment for chemotherapy refractory metastatic breast carcinoma is not recommended. This regimen may, however, be employed as second line chemotherapy in selected cases.